BR112021016642A2 - Derivados de pirazolopiridina como inibidores de pask - Google Patents

Derivados de pirazolopiridina como inibidores de pask

Info

Publication number
BR112021016642A2
BR112021016642A2 BR112021016642A BR112021016642A BR112021016642A2 BR 112021016642 A2 BR112021016642 A2 BR 112021016642A2 BR 112021016642 A BR112021016642 A BR 112021016642A BR 112021016642 A BR112021016642 A BR 112021016642A BR 112021016642 A2 BR112021016642 A2 BR 112021016642A2
Authority
BR
Brazil
Prior art keywords
inhibitors
pask
pyrazolopyridine derivatives
treatment
methods
Prior art date
Application number
BR112021016642A
Other languages
English (en)
Portuguese (pt)
Inventor
Marie Joncour Agnès
COMAS MARTINEZ Daniel
Gilbert Labéguère Frédéric
López Ramos Miriam
Nicolas Alain Beaumont Stéphane
Taoues Temal-Laib
Marie Bock Xavier
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of BR112021016642A2 publication Critical patent/BR112021016642A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112021016642A 2019-02-25 2020-02-17 Derivados de pirazolopiridina como inibidores de pask BR112021016642A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1902490.0A GB201902490D0 (en) 2019-02-25 2019-02-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PCT/EP2020/054122 WO2020173739A1 (en) 2019-02-25 2020-02-17 Pyrazolopyridine derivatives as inhibitors of pask

Publications (1)

Publication Number Publication Date
BR112021016642A2 true BR112021016642A2 (pt) 2021-11-03

Family

ID=65998935

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016642A BR112021016642A2 (pt) 2019-02-25 2020-02-17 Derivados de pirazolopiridina como inibidores de pask

Country Status (19)

Country Link
US (1) US20220144823A1 (cg-RX-API-DMAC7.html)
EP (1) EP3931191B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022525121A (cg-RX-API-DMAC7.html)
KR (1) KR20210134001A (cg-RX-API-DMAC7.html)
CN (1) CN113474344A (cg-RX-API-DMAC7.html)
AR (1) AR124749A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020229041A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016642A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130154A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021010485A2 (cg-RX-API-DMAC7.html)
ES (1) ES2963409T3 (cg-RX-API-DMAC7.html)
GB (1) GB201902490D0 (cg-RX-API-DMAC7.html)
IL (1) IL285751A (cg-RX-API-DMAC7.html)
MA (1) MA55074A (cg-RX-API-DMAC7.html)
MX (1) MX2021010093A (cg-RX-API-DMAC7.html)
PH (1) PH12021552032A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109157TA (cg-RX-API-DMAC7.html)
TW (1) TW202045505A (cg-RX-API-DMAC7.html)
WO (1) WO2020173739A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022070288A1 (ja) * 2020-09-30 2022-04-07 旭化成ファーマ株式会社 含窒素二環化合物
WO2025143152A1 (ja) * 2023-12-27 2025-07-03 全薬工業株式会社 チアゾリル-ピラゾロ[1,5-a]ピリジン化合物、およびそのMYLK4阻害剤としての使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2048142A3 (en) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
CA2732520A1 (en) * 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
JP2012516329A (ja) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ, インコーポレイテッド Pi3k阻害剤としてのヘテロアリールおよびその使用
WO2014066795A1 (en) * 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
EP3227286B1 (de) * 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
JP7175917B2 (ja) * 2017-04-27 2022-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 新規のalk2阻害剤及びbmpシグナル伝達の阻害方法

Also Published As

Publication number Publication date
CN113474344A (zh) 2021-10-01
PH12021552032A1 (en) 2022-11-14
WO2020173739A1 (en) 2020-09-03
IL285751A (en) 2021-10-31
SG11202109157TA (en) 2021-09-29
MA55074A (fr) 2022-01-05
JP2022525121A (ja) 2022-05-11
KR20210134001A (ko) 2021-11-08
GB201902490D0 (en) 2019-04-10
EP3931191A1 (en) 2022-01-05
EP3931191B1 (en) 2023-10-04
ES2963409T3 (es) 2024-03-27
TW202045505A (zh) 2020-12-16
AU2020229041A1 (en) 2021-10-21
CA3130154A1 (en) 2020-09-03
MX2021010093A (es) 2021-09-21
CO2021010485A2 (es) 2021-08-19
US20220144823A1 (en) 2022-05-12
AR124749A1 (es) 2023-05-03

Similar Documents

Publication Publication Date Title
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
SV2018005742A (es) Inhibidores de mcl-1 macrocíclicos para tratar el cáncer
MX2020011085A (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim.
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112017026132A2 (pt) piridinas substituídas e métodos de uso
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
CO2018004124A2 (es) Compuestos heterocíclicos
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112019007609A2 (pt) ciclobutano 1,3 di-substituído ou derivados de azetidina como inibidores de sintase de prostaglandina d hematopoiética
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
BR112017013258A8 (pt) Derivados de 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidina-2,4-diona como inibidores de adamts para o tratamento de osteoartrite
SA520412289B1 (ar) مركبات مثبط الهدف الميكانيكي للراباميسين
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
MD20140044A2 (ro) 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
BR112016020556A8 (pt) compostos, composição farmacêutica, método de modulação da atividade do receptor de grelina, método para o tratamento de uma doença e usos de um composto
BR112018076734A2 (pt) compostos heterocíclicos anti-infecciosos e usos dos mesmos

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.